SIMRIS ALG AB CONFIRMS GRANTING OF JAPANESE PATENT COVERING THE MODIFICATION OF MICROCYSTINS
· The patent provides broad protection for a platform technology covering the modification of microcystins; a novel ADC payload class with a unique, multimodal and universal mode of action. · The family of patents is now granted in Europe, UK, USA, Australia and JapanSimris Alg AB (publ), a biologics company listed on the Swedish Nasdaq stock exchange and specialising in the extraction of high value biological compounds from microalgae and cyanobacteria, announced today that its patent for Microcystin-based ADCs has been granted in Japan. Julian Read, CEO at Simris Alg AB, commented: